Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis.

Lauder, Lucas; Pereira, Tiago V; Degenhardt, Markus C; Ewen, Sebastian; Kulenthiran, Saarraaken; Coats, Andrew J S; Böhm, Michael; Anker, Stefan D; da Costa, Bruno R.; Mahfoud, Felix (2021). Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis. European journal of heart failure, 23(11), pp. 1960-1970. Wiley 10.1002/ejhf.2360

Preview

Text Lauder_EurJHeartFail_2021.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (883kB) | Preview

AIMS

To assess the feasibility and efficacy of interatrial shunt devices (IASD) for the treatment of chronic heart failure (CHF).

METHODS

MEDLINE and the Cochrane Central Register of Controlled Trials from inception until April 2021 were searched for prospective studies investigating dedicated transcatheter IASD for the treatment of CHF. Standardised mean differences were calculated for the within-group changes before and after implantation of the IASD. The predefined primary outcome was change in six-minute walking distance (6MWD) from baseline to 12 months. Other outcomes were change in NYHA class, health-related quality of life (HRQoL), echocardiographic and hemodynamic data, device performance and safety. Subgroup analyses were crude univariable meta-regression analyses.

RESULTS

Six studies (five single-arm open-label studies, one sham-controlled trial) were included. In these, 226 patients underwent IASD implantation using four different devices. From baseline to 12 months, 6MWD increased by 28.1 m (95% CI: 10.9 to 45.3) with no evidence for a difference between devices (p for interaction = 0.66) and patients with left-ventricular ejection fraction (LVEF) >40% or ≤ 40% (p for interaction = 0.21). At 12 months, HRQoL improved by 17.7 points (95% CI: 10.8 to 24.6) and pulmonary capillary wedge pressure (PCWP) decreased by 2.0 mmHg (95% CI: -3.6 to -0.4), respectively. There were no changes in LVEF or NT-proBNP during follow-up. Shunt patency ranged from 50% for the first-generation v-Wave to 100% for the Corvia IASD II and the second-generation v-Wave system. The summary risk of serious adverse device-related effects was 8% (95% CI: 1 to 20) at 12 months.

CONCLUSION

IASD implantation in CHF is feasible and associates with improved submaximal exercise capacity (measured by 6MWD) and HRQoL, and reductions in PCWP. This article is protected by copyright. All rights reserved.

Interest & Impact

Downloads

137 since deposited on 14 Oct 2021
69 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item